M42's ICLDC to open Al Dhafra's first one-stop tech-enabled diabetes facility.

 ICLDC's new dedicated facility in Madinat Zayed, Abu Dhabi, marks a significant milestone in the region by offering comprehensive care for diabetes and endocrine patients. As part of the M42 group, the Imperial College London Diabetes Centre will provide world-class, tech-enabled services to more than 6,000 individuals in the Al Dhafra region, significantly reducing travel time and increasing access to care.

The state-of-the-art facility is set to open in the second half of the year and aims to bring comprehensive care closer to those in need. Currently, the flagship ICLDC in Abu Dhabi city serves approximately 9 percent of the Al Dhafra population affected by diabetes. The new centre in Madinat Zayed will extend the reach of care to residents in areas such as Liwa, Mirfa, Gayathi, Ruwais, and Tarif.

In addition to clinical care, the Imperial College London Diabetes Centre will continue its efforts in promoting preventive solutions for Type 2 diabetes. The centre will conduct community outreach programs, including workshops, health screenings, and educational initiatives for schools and organizations. These efforts will focus on encouraging an active lifestyle and promoting healthy eating habits.

Hasan Jasem Al Nowais, the Managing Director and Group CEO of M42, expressed the commitment of the organization to provide world-class health solutions and empower individuals to take control of their health. The expansion of ICLDC's services to Al Dhafra presents an opportunity to serve a larger number of UAE residents with innovative, tech-enabled healthcare solutions that result in positive clinical outcomes.

Over nearly two decades, ICLDC has played a pivotal role in revolutionizing population health in the UAE. Through its model for diabetes prevention and management, the centre has achieved significant reductions in HbA1c levels among patients. On average, HbA1c values have dropped from 9.5 percent to an impressive 7.2 percent, with 57 percent of patients now having HbA1c results below the international benchmark of 7 percent. These outstanding outcomes highlight the expertise and dedication of ICLDC's team of over 65 consultants in diabetes and endocrine care.

The new ICLDC centre in Al Dhafra will be equipped with the latest diagnostic and management facilities and supported by a world-class multi-specialty team. It will provide specialized care for diabetes and endocrine-related complications through state-of-the-art outpatient services.

Dr. Mai Al Jaber, CEO of ICLDC, emphasized the importance of accessible and comprehensive diabetes care and expressed the organization's commitment to serving more of the Al Dhafra population. The goal is to provide patient-centric and comprehensive diabetes and endocrinology solutions under one roof and closer to home.

The Madinat Zayed facility will be ICLDC's fourth dedicated facility in the UAE, complementing its satellite clinic based in Mubadala Health Dubai. The new clinic will offer a seamless patient journey, encompassing registration, consultations, and pharmacy support, all within a comprehensive and integrated healthcare environment.

ICLDC's expansion into Al Dhafra reflects its dedication to improving the lives of individuals affected by diabetes and endocrine disorders. By providing accessible and high-quality care, the centre aims to make a positive impact on the health and well-being of the community it serves.